Audit of diagnostic tissue for the diagnosis of non-small cell lung cancer
Keywords:
Lung cancer, Cancer, EGFR, ALK, biomarkerAbstract
Background: Non-small cell lung cancer (NSCLC) harbouring Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations respond well to tyrosine kinase inhibitors (TKIs). This response is better than that seen with standard chemotherapy. Adequate tissue specimens are necessary for accurate identification of biomarkers in NSCLC to determine subtype and targeted treatment. The aim of this study is to ascertain which biopsy method provides the highest proportion of adequate tissue specimens for biomarker testing.
Methods:The Mosaiq® database was accessed to retrieve information regarding all (164) patients diagnosed with NSCLC between 12/02/2011-15/2/13. The biopsy methods used, patient characteristics and adequacy of tissue obtained for biomarker testing were analysed using the SPSS software.
Result: From the 41 patients tested for biomarkers, surgical resection provided the highest proportion of adequate tissue specimens (100%) compared with fine needle (89%) and core biopsy (61%) respectively.
Conclusion: In conclusion, patients with NSCLC who are unsuitable for surgery, fine needle biopsy can be considered before core biopsy for biomarker testing given the higher proportion of adequate tissue specimens obtained. Larger scale trials are required to assess tissue acquisition, processing and reporting for biomarker testing in order to standardise detection of driver mutations for personalised cancer therapy.
References
1. Crino L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;103(21).
2. Government A. Lung Cancer Statistics. In: Australia C, editor. Sydney2013.
3. Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer. 2011;74(1):1-6.
4. Langer CJ. Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. Crit Rev OncolHematol. 2012;83(1):130-44.
5. Society AC. Non small cell lung cancer survival rates by stage. 2013 [updated 12/7/2013; cited 2013 1 October]; Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates.
6. Dacic. Molecular Testing of Lung Carcinoma. Pathology Case Reviews. 2014;19(1):36-9.
7. Canberra AIoHaW. Lung Cancer in Australia- an overview. In: AIHW, editor. Canberra 2011.
8. Sakashita S, Sakashita M, Sound Tsao M. Genes and pathology of non-small cell lung carcinoma. SeminOncol. 2014;41(1):28-39.
9. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J ThoracOncol. 2011;6(2):244-85.
10. Lim EH, Zhang SL, Yu K, Nga ME, Ahmed DA, Agasthian T, et al. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. J ThoracOncol. 2007;2(5):387-96.
11. Institute NC. Non-Small Cell Lung Cancer Treatment (PDQ). National Institue of Health; 2013 [updated 30/05/20132013 September 29]; Available from: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page1.
12. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev ClinOncol. 2010;7(7):401-14.
13. Tsao MS. Molecular testing to personalise EGFR and ALK inhibitor therapies in lung cancer. American Association for Cancer Research.2014 15 January 2014.
14. Marchetti A, Ardizzoni A, Papotti M, Crinò L, Rossi G, Gridelli C, et al. Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. Journal of Thoracic Oncology. 2013;8(3):352-8 10.1097/JTO.0b013e31827d5280.
15. Reck M. A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Rev Anticancer Ther. 2010;10(6):955-65.
16. NIH. EGFR-TK mutation testing in adults with locally advanced or metastatic non small cell lung cancer. In: Excellence NIfHca, editor.: NICE; 2013.
17. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer: J Carcinog. 2013 Dec 31;12:22. eCollection 2013.
18. Hlinkova K, Babal P, Berzinec P, Majer I, Mikle-Barathova Z, Piackova B, et al. Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples. DiagnMolPathol. 2013;22(2):70-5.
19. MSAC. MSAC Application document 1173: Final Decision Analytical Protocol(DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for erlotinib treatment as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer(NSCLC). In: Ageing DoHa, editor.2012.
20. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J ClinOncol. 2011;29(15):2121-7.
21. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;16:16.
22. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J ThoracOncol. 2013;8(7):823-59.
23. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J ClinPathol. 2013;66(2):79-89.
24. Lindeman NI CP, Beasley MB et al. Molecular testing guidelines for slection of lung cancer patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guidelines from the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), Association for Molecular Pathology (AMP). Arch Pathol Lab Med.
25. Fassina A, Cappellesso R, Simonato F, Lanza C, Marzari A, Fassan M. Fine needle aspiration of non-small cell lung cancer: current state and future perspective. Cytopathology. 2012;23(4):213-9.
26. Sekhon HS, Souza CA, Gomes MM. Advances in cytopathology for lung cancer: the impact and challenges of new technologies. ThoracSurgClin. 2013;23(2):163-78.
27. G K. Challenges in NSCLC testing- Barriers to implementation2012; 11(4): Available from: http://www.oncologyex.com/pdf/vol11_no4/comment_nsclc-molecular-testing.pdf.
28. Pirker R, Herth FJF, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology. 2010;5(10):1706-13 10.097/JTO.0b013e3181f1c8de.
29. Sun MH, Yang F, Shen L, Zhang L, Chen Y, Cai X, et al. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types]. Zhonghua Bing Li XueZaZhi. 2011;40(10):655-9.
30. Ma ES, Ng WK, Wong CL. EGFR gene mutation study in cytology specimens. ActaCytol. 2012;56(6):661-8.
31. B S. Core needle lung biopsy specimens:adequacy for EGFR and KRAS mutational analysis. Amerian journal of roentgenology. 2010 01/2010;194(1):266-9.
32. Smouse J CD, Edmund S, Janne P, Joshi V, Zou K, Lindeman N. EGFR mutations are detected comparably in cytological and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathology. 2009 2009;117(1):67-72.
33. Hagiwara K, Kobayashi K. Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. Cancer Science. 2013;104(3):291-7.
34. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461(3):245-57.
2. Government A. Lung Cancer Statistics. In: Australia C, editor. Sydney2013.
3. Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer. 2011;74(1):1-6.
4. Langer CJ. Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. Crit Rev OncolHematol. 2012;83(1):130-44.
5. Society AC. Non small cell lung cancer survival rates by stage. 2013 [updated 12/7/2013; cited 2013 1 October]; Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates.
6. Dacic. Molecular Testing of Lung Carcinoma. Pathology Case Reviews. 2014;19(1):36-9.
7. Canberra AIoHaW. Lung Cancer in Australia- an overview. In: AIHW, editor. Canberra 2011.
8. Sakashita S, Sakashita M, Sound Tsao M. Genes and pathology of non-small cell lung carcinoma. SeminOncol. 2014;41(1):28-39.
9. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J ThoracOncol. 2011;6(2):244-85.
10. Lim EH, Zhang SL, Yu K, Nga ME, Ahmed DA, Agasthian T, et al. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. J ThoracOncol. 2007;2(5):387-96.
11. Institute NC. Non-Small Cell Lung Cancer Treatment (PDQ). National Institue of Health; 2013 [updated 30/05/20132013 September 29]; Available from: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page1.
12. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev ClinOncol. 2010;7(7):401-14.
13. Tsao MS. Molecular testing to personalise EGFR and ALK inhibitor therapies in lung cancer. American Association for Cancer Research.2014 15 January 2014.
14. Marchetti A, Ardizzoni A, Papotti M, Crinò L, Rossi G, Gridelli C, et al. Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. Journal of Thoracic Oncology. 2013;8(3):352-8 10.1097/JTO.0b013e31827d5280.
15. Reck M. A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Rev Anticancer Ther. 2010;10(6):955-65.
16. NIH. EGFR-TK mutation testing in adults with locally advanced or metastatic non small cell lung cancer. In: Excellence NIfHca, editor.: NICE; 2013.
17. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer: J Carcinog. 2013 Dec 31;12:22. eCollection 2013.
18. Hlinkova K, Babal P, Berzinec P, Majer I, Mikle-Barathova Z, Piackova B, et al. Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples. DiagnMolPathol. 2013;22(2):70-5.
19. MSAC. MSAC Application document 1173: Final Decision Analytical Protocol(DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for erlotinib treatment as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer(NSCLC). In: Ageing DoHa, editor.2012.
20. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J ClinOncol. 2011;29(15):2121-7.
21. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;16:16.
22. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J ThoracOncol. 2013;8(7):823-59.
23. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J ClinPathol. 2013;66(2):79-89.
24. Lindeman NI CP, Beasley MB et al. Molecular testing guidelines for slection of lung cancer patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guidelines from the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), Association for Molecular Pathology (AMP). Arch Pathol Lab Med.
25. Fassina A, Cappellesso R, Simonato F, Lanza C, Marzari A, Fassan M. Fine needle aspiration of non-small cell lung cancer: current state and future perspective. Cytopathology. 2012;23(4):213-9.
26. Sekhon HS, Souza CA, Gomes MM. Advances in cytopathology for lung cancer: the impact and challenges of new technologies. ThoracSurgClin. 2013;23(2):163-78.
27. G K. Challenges in NSCLC testing- Barriers to implementation2012; 11(4): Available from: http://www.oncologyex.com/pdf/vol11_no4/comment_nsclc-molecular-testing.pdf.
28. Pirker R, Herth FJF, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology. 2010;5(10):1706-13 10.097/JTO.0b013e3181f1c8de.
29. Sun MH, Yang F, Shen L, Zhang L, Chen Y, Cai X, et al. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types]. Zhonghua Bing Li XueZaZhi. 2011;40(10):655-9.
30. Ma ES, Ng WK, Wong CL. EGFR gene mutation study in cytology specimens. ActaCytol. 2012;56(6):661-8.
31. B S. Core needle lung biopsy specimens:adequacy for EGFR and KRAS mutational analysis. Amerian journal of roentgenology. 2010 01/2010;194(1):266-9.
32. Smouse J CD, Edmund S, Janne P, Joshi V, Zou K, Lindeman N. EGFR mutations are detected comparably in cytological and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathology. 2009 2009;117(1):67-72.
33. Hagiwara K, Kobayashi K. Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. Cancer Science. 2013;104(3):291-7.
34. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461(3):245-57.
Downloads
Published
09-08-2016
How to Cite
1.
Dean MR, Della-Fiorentine S. Audit of diagnostic tissue for the diagnosis of non-small cell lung cancer. Ann of Pathol and Lab Med [Internet]. 2016 Aug. 9 [cited 2024 Nov. 19];3(3):A128-133. Available from: https://pacificejournals.com/journal/index.php/apalm/article/view/apalm803
Issue
Section
Original Article
License
Copyright (c) 2016 Madeeha Ruqaiya Dean, Stephen Della-Fiorentine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).